general

Amplia gets nod for new cancer drug trial ahead of US push

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Reported by The Age
Read the complete report at The Age ↗
Verification notice

IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.

INCIDENT FUSION

4 reports · 4 sources

The AgeAmplia gets nod for new cancer drug trial ahead of US pushSydney Morning HeraldAmplia gets nod for new cancer drug trial ahead of US pushThe AgeAmplia gets nod for new cancer drug trial ahead of US pushSydney Morning HeraldAmplia gets nod for new cancer drug trial ahead of US push
INCIDENT EVOLUTION

3 recorded states

Signal first indexedP1 · 99% quality · 3 sources

Corroboration 3→4 sourcesP1 · 99% quality · 4 sources

Corroboration 4→3 sourcesP1 · 99% quality · 3 sources

Explore this day in the archive →
QUALITY CONTROL

Report this signal

Reports are anonymous and retained privately for editorial review.